Holen Sie sich die Stockscreener-App
1.04
12.68%
0.117
Handel nachbörslich:
1.04
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - The AI Journal
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
Oncolytics Biotech says data backs pelareorep in KRAS-mutant mCRC - marketscreener.com
Oncolytics Biotech Reports Promising Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer By Investing.com - Investing.com South Africa
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - Yahoo Finance
United States Oncolytic Virus Therapy Market to Reach USD 199.98 - openPR.com
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Cantech Letter
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion - The Globe and Mail
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Oncolytics Biotech Plans Jurisdiction Shift to Nevada - The Globe and Mail
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech reschedules shareholder vote on U.S. domicile move By Investing.com - Investing.com Nigeria
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporat - pharmiweb.com
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - The AI Journal
Oncolytics Biotech Reschedules Special Meeting Of Shareholders To Change Jurisdiction Of Incorporation To Nevada - TradingView — Track All Markets
Published on: 2025-12-08 13:44:04 - moha.gov.vn
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality - The Manila Times
Oncolytics to test immunotherapy against aggressive pancreatic cancer - Rare Cancer News
Is Oncolytics Biotech Inc. stock dividend yield sustainableMarket Volume Summary & Low Risk Profit Maximizing Plans - Newser
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - sharewise.com
Is Oncolytics Biotech Inc. stock undervalued vs historical averages2025 Historical Comparison & Weekly Watchlist for Hot Stocks - Newser
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality - The Globe and Mail
ONCY: Virtual Meeting Scheduled for December 8 - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Oncolytics Biotech Inc. stock a buy for dividend growthJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire) - Aktiellt
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - Aktiellt
Oncolytics Biotech Reports Q3 2025 Financial Results - TipRanks
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire) - Aktiellt
This Canadian biotech stock is tackling pancreatic Cancer - Cantech Letter
Are Analysts Too Optimistic About Nagreeka Capital Infrastructure Ltds Revenue GrowthGap Up/Gap Down Analysis & Achieve Consistent Profits - earlytimes.in
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital - The Globe and Mail
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - MSN
Can Oncolytics Biotech Inc. stock sustain free cash flow growthJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - newser.com
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - BioSpace
Can Oncolytics Biotech Inc. stock attract ESG capital inflowsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - The Globe and Mail
Identifying reversal signals in Oncolytics Biotech Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Nigeria
Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat
Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media
Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace
Oncolytics Biotech provides update on special meeting of shareholders - marketscreener.com
Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com
0.39%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):